NEW YORK (GenomeWeb News) – Curie-Cancer today announced two three-year partnerships between Institute Curie and French biotech firm Meiogenix to further develop that firm's meiotic recombination technology.

Under the terms of the deals, the technology called SpiX, short for Spo11-based technology, will be used in yeast and mice "to exploit the unexplored natural biodiversity of organisms."

Financial and other terms of the deals were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.